Fibrinogen is a protein in the blood plasma that is essential for the coagulation of blood and is converted to fibrin by the action of thrombin in the presence of ionized calcium. Human fibrinogen is a protein which is important for blood clotting (coagulation).
The industry is concentration, the key brand include CSL Behring, LFB, Shanghai RAAS, Boya, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, Greencross, Shanghai XinXing Medical and so on. Among them, CSL Behring and LFB are the leaders.
The leading companies own the advantages on better performance, more abundant product’s types, better technical and impeccable after-sales service. Consequently, they take the majority of the market share of high-end market. Looking to the future years, the slow downward price trend in recent years will maintain. As competition intensifies, prices gap between different brands will go narrowing. Similarly, there will be fluctuation in gross margin.
The industry is expected to remain innovation-led, with frequent acquisitions and strategic alliances adopted as the key strategies by the players to increase their industry presence. Market stays in mature period with a clear concentration. Meanwhile, optimize product mix and further develop value-added capabilities to maximize margins.
Significant and lasting barriers make entry into this market difficult. These barriers include, but are not limited to: (i) product development costs; (ii) capital requirements; (iii) intellectual property rights; (iv) regulatory requirement; and (v) Transitions’ unfair methods of competition.
Despite the presence of competition problems, due to the global recovery trend is clear, investors are still optimistic about this area, the future will still have more new investment enter the field. Even so, the market is intensely competitive .The study group recommends the new entrants just having money but without technical advantage and upstream and downstream support do not to enter into this field.
The global Human Fibrinogen market is valued at 470 million US$ in 2018 is expected to reach 2820 million US$ by the end of 2025, growing at a CAGR of 25.0% during 2019-2025.
This report focuses on Human Fibrinogen volume and value at global level, regional level and company level. From a global perspective, this report represents overall Human Fibrinogen market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
CSL Behring
LFB
Shanghai RAAS
Boya
Hualan Biological Engineering
Harbin Pacific Biopharmaceutical
Greencross
Shanghai XinXing Medical
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Pure Human Fibrinogen
Fibrinogen Concentrate (Human)
Segment by Application
Congenital Fibrinogen Deficiency
Surgical Procedures
Summary:
Get latest Market Research Reports on Human Fibrinogen . Industry analysis & Market Report on Human Fibrinogen is a syndicated market report, published as Global Human Fibrinogen Market Research Report 2019. It is complete Research Study and Industry Analysis of Human Fibrinogen market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.